International Assets Investment Management LLC Acquires 58,299 Shares of Repligen Co. (NASDAQ:RGEN)

International Assets Investment Management LLC boosted its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 18,449.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 58,615 shares of the biotechnology company's stock after acquiring an additional 58,299 shares during the quarter. International Assets Investment Management LLC owned 0.10% of Repligen worth $10,539,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in RGEN. PNC Financial Services Group Inc. increased its position in Repligen by 6.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,723 shares of the biotechnology company's stock worth $1,077,000 after buying an additional 333 shares during the period. Great West Life Assurance Co. Can grew its holdings in shares of Repligen by 8.2% during the first quarter. Great West Life Assurance Co. Can now owns 28,126 shares of the biotechnology company's stock worth $5,427,000 after purchasing an additional 2,143 shares during the last quarter. Raymond James Trust N.A. boosted its holdings in Repligen by 37.4% in the first quarter. Raymond James Trust N.A. now owns 2,331 shares of the biotechnology company's stock valued at $438,000 after acquiring an additional 634 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Repligen by 5.1% in the first quarter. Dimensional Fund Advisors LP now owns 229,785 shares of the biotechnology company's stock valued at $43,221,000 after acquiring an additional 11,121 shares during the last quarter. Finally, Sei Investments Co. boosted its holdings in Repligen by 18.5% in the first quarter. Sei Investments Co. now owns 59,917 shares of the biotechnology company's stock valued at $11,331,000 after acquiring an additional 9,352 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Stock Down 2.6 %

Shares of NASDAQ RGEN traded down $4.55 during mid-day trading on Friday, reaching $171.53. 706,402 shares of the company's stock were exchanged, compared to its average volume of 386,813. The firm has a market capitalization of $9.58 billion, a price-to-earnings ratio of 238.24, a PEG ratio of 5.77 and a beta of 1.02. The company has a current ratio of 7.02, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26. The business has a fifty day simple moving average of $192.16 and a 200 day simple moving average of $173.13. Repligen Co. has a twelve month low of $110.45 and a twelve month high of $211.13.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, hitting analysts' consensus estimates of $0.33. The company had revenue of $155.74 million for the quarter, compared to analyst estimates of $155.38 million. Repligen had a return on equity of 5.00% and a net margin of 6.51%. Repligen's revenue was down 16.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.68 earnings per share. As a group, equities analysts expect that Repligen Co. will post 1.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. JPMorgan Chase & Co. raised their price target on Repligen from $170.00 to $210.00 and gave the company an "overweight" rating in a report on Wednesday, December 20th. Stifel Nicolaus increased their target price on Repligen from $165.00 to $207.00 and gave the company a "buy" rating in a research note on Thursday, February 22nd. Finally, KeyCorp increased their target price on Repligen from $210.00 to $220.00 and gave the company an "overweight" rating in a research note on Thursday, February 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Repligen has a consensus rating of "Moderate Buy" and an average target price of $196.70.

Insider Activity at Repligen

In related news, COO James Bylund sold 4,373 shares of Repligen stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total value of $866,203.84. Following the sale, the chief operating officer now owns 14,135 shares of the company's stock, valued at approximately $2,799,860.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the firm's stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the transaction, the vice president now directly owns 24,260 shares in the company, valued at $4,699,889.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO James Bylund sold 4,373 shares of the firm's stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total value of $866,203.84. Following the completion of the transaction, the chief operating officer now owns 14,135 shares of the company's stock, valued at $2,799,860.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 25,597 shares of company stock valued at $5,039,532. 1.10% of the stock is owned by insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.